EWTX - Edgewise Therapeutics | Satya Bio Analysis

Edgewise is positioned to become a commercial company in 2027 with sevasemten as the first approved therapy for Becker muscular dystrophy, addressing a ~$5B market opportunity, while EDG-7500's differentiated cardiac mechanism could capture significant share of the ~$10B HCM market without the heart failure risks of current competitors.

Investment Thesis

Bull Case

Sevasemten targets a disease (Becker) with zero FDA-approved therapies and clear regulatory path (FDA Type C meeting confirmed GRAND CANYON as single adequate study for registration)
GRAND CANYON is highly powered (N=175) for NSAA primary endpoint over 18 months; MESA OLE shows sustained stabilization after 3 years of treatment
CANYON Phase 2 met primary endpoint (CK reduction) and showed NSAA stabilization vs placebo at 12 months — 0.8 point improvement from baseline in MESA rollover
Commercial infrastructure being built for potential 2027 launch; Orphan Drug and Fast Track designations secured for both Becker and Duchenne
EDG-7500 HCM data showing improvements in NT-proBNP, KCCQ, NYHA and LVOT gradient; Phase 3 targeted H2 2026

Bear Case

GRAND CANYON is a binary event — entire thesis depends on showing statistically significant NSAA difference vs placebo at 18 months
FDA deemed CANYON data alone insufficient for accelerated approval, requiring the larger GRAND CANYON study
Becker is a rare disease (~3,500-5,000 US patients) which may limit peak sales potential
Pre-revenue company with Q3 2025 net loss of $40.7M and no approved products
EDG-7500 had one AF event in Part D (deemed not drug-related) — cardiac safety monitoring is ongoing concern for sarcomere modulators

Pipeline

Asset	Target	Stage	Lead Indication	Next Catalyst
EDG-003	Undisclosed target	Preclinical	Cardiometabolic diseases	—
EDG-15400	Undisclosed cardiac sarcomeric target	Phase 1	Heart Failure with Preserved Ejection Fraction (HFpEF)	Phase 1 EDG-15400 healthy volunteer data (H1 2026)
EDG-7500	Cardiac sarcomeric target	Phase 2	Hypertrophic Cardiomyopathy	CIRRUS-HCM Part D Phase 2 results in oHCM & nHCM (H1 2026)
Sevasemten	Fast skeletal myosin ATPase	Pivotal	Becker muscular dystrophy	GRAND CANYON Pivotal Trial Readout (End of year 2026)